Name | Title | Contact Details |
---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Brickhouse Martin Healthcare Engineering is a Centreville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Q² Solutions, a Quintiles Quest joint venture Launched in 2015, Q² Solutions (pronounced Q-squared) is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q² Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities.
Q-One Biotech is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Envoy Medical Corporation is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.